Sun Pharmaceutical Industries Limited announced that it has received final approval from US FDA for its Abbreviated New Drug Application for generic Mesalamine Extended Release Capsules, 500 mg. The generic product approval is based on Pentasa Extended Release Capsules, 500mg as a reference product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,525 INR | +1.23% | +0.92% | +21.09% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.09% | 43.27B | |
+25.28% | 22.92B | |
+19.22% | 15.43B | |
+13.51% | 12.95B | |
+44.01% | 11.83B | |
-7.79% | 6.91B | |
-0.05% | 6.79B | |
-8.87% | 5.73B | |
+13.02% | 5.55B | |
+9.14% | 4.9B |
- Stock Market
- Equities
- SUNPHARMA Stock
- News Sun Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Limited Receives US FDA Approval for Generic Mesalamine Extended Release Capsules